Introduction
============

Pneumothorax may be primary, in which no obvious trigger is identified, or secondary, which may be induced by trauma or iatrogenic factors. The iatrogenic factors typically cited include subclavian line placement, needle thoracentesis, and pleural biopsy.[@B1]

Another category of reported iatrogenic factors is drugs, although pneumothorax is probably not typically thought of as an adverse drug event (ADE). The most commonly cited drugs in the published literature include oncology drugs, although other drugs, such as nitrous oxide, inhaled pentamidine and those associated with pulmonary fibrosis are also represented.[@B2]-[@B17] The prominent association of oncology drugs with pneumothorax is intriguing and challenging to understand, as pneumothorax could theoretically be an epiphenomenon of drug efficacy (i.e. chemotherapy-induced lysis of sub-pleural tumor deposits) or inefficacy in this setting (i.e. progression of subpleural tumor deposits due to lack of efficacy). Confounding by indication (CBI)[@B18] is therefore an important consideration, given that pneumothorax may reflect the natural history/complications of malignancy.[@B19]-[@B21] There is variation in the use of the term CBI[@B14] but for our purposes CBI means that the treatment indication is independently associated with the ADE. It is difficult to exclude one of the aforementioned possibilities. Further complicating these associations are the co-occurrence of cancers and pneumothorax as part of a syndromic phenotype, such as the association of renal cell carcinoma and pneumothorax as elements of Birt-Hogg-Dube syndrome.[@B22],[@B23]

Most of the published literature on pneumothorax consists of case reports. As pharmacovigilance (PhV) specialists we routinely access and analyze rich sources of ADEs such as large spontaneous reporting systems (SRS) maintained by health authorities. We were curious to discover and better understand the representation of pneumothorax as an ADE in these data sets.

Herein we present an analysis of the data of pneumothorax as a reported ADE in a large health authority post-approval drug safety database. The primary objective is to increase scientific understanding of this spontaneous reporting association.[@B24] A secondary objective is to present an adaptation of an "old" epidemiological concept, Cornfield\'s inequality,[@B25] that is novel for the application domain of PhV,[@B26] to explore the potential role of CBI in the association of pneumothorax for a subset of drugs for which this is an especially apt consideration. This could support real-world PhV because when drug-event combinations of interest are initially identified that could represent a signal of a novel association, an analyst will typically perform a first pass qualitative triage based on scientific judgment that includes consideration of CBI.[@B27] A CBI analysis of this sort therefore has the potential to provide quantitative decision support for first pass triage in PhV.

Methodology
===========

1. Databases {#Section1}
------------

The data set analyzed was the United States Food and Drug Administration (US FDA) Adverse Event Reporting System (AERS) database. AERS is a spontaneous reporting system (SRS) database for post-approval safety surveillance that serves as an early warning system for ADEs not detected in pre-approval testing.[@B24] The AERS database was analyzed from January 1^st^, 1969 through December 31^st^, 2010. The data was preprocessed to reduce redundant drug nomenclature and duplicate reports. Suspected adverse drug reactions are coded with hierarchical medical thesaurus known as the Medical Dictionary for Regulatory Activities (MedDRA).[@B28] The hierarchy maps the verbatim reported term to a Lower level Term (LLT) and then to a Preferred Term (PT) in the hierarchy, that is intended to capture a given medical concept in a standardized manner.[@B28]

2. Statistical Analysis Methodology {#Section2}
-----------------------------------

We performed two-dimensional (2-D) disproportionality analysis (DA) limited to suspect drugs. DA calculates the number of reports, proportionate representation, or odds of a given 2-D drug-event combination (DEC), that would be expected based on chance spontaneous reporting and recording of the corresponding drug(s) and event(s) in the database. In combination with the number of reports actually observed, an observed-to-expected ratio of reporting frequencies, ratios or odds is calculated (O/E).[@B24] There are variations in the specific implementation of DA with SRS data including frequentist and Bayesian formulations. No single method has been proven to be the method-of-choice. Details on DA may be found in the published literature[@B24],[@B29]

We used a form of DA known as the multi-item gamma-Poisson shrinker (MGPS) (Oracle, Redwood Shores, CA) for this analysis. This algorithm models reporting frequencies as realizations of a Poisson process in which the Poisson parameter is itself considered a random variable whose distribution is a mixture of two gamma distributions. The initial parameters of the gamma mixture are determined using a negative binomial maximum likelihood algorithm to determine the prior probabilities of different possible O/E ratios. Prior probabilities are updated based on the number of reports of the DEC of interest using Baye\'s rule. In effect this calculates each O/E ratio as a composite of the grand mean O/E of all reported DECs, which is close to one (Hauben M, unpublished data) and that of the combination of interest, with the weighting for each determined by the O and E counts. When one or both of these counts are low the grand mean is heavily weighted but as information is gained, the individual combination\'s O/E is weighed more heavily and may eventually dominate the calculation.

The O/E metric calculated is the empirical Bayes geometric mean (EBGM) and its associated 90% posterior interval (PI) defined by the lower 5^th^ (EB05) and upper 95^th^ (EB95) percentiles of the EBGM.[@B24] An EB05\>2 was used to define an interestingly large O/E,[@B30]-[@B32] also known as a \'signal of disproportionate reporting (SDR).[@B33] Calculations were performed at the MedDRA PT level. Basic covariate stratification by age, gender and year of report was performed to mitigate the effects of confounding by these variables and calculate a summary Mantel-Haenszel type O/E ratio.

We also performed the calculation for drug-indication pairs. This was inspired by Cornfield\'s inequality that in order for an effect with a relative risk (RR) of some magnitude X to be *fully*explainable by a confounding factor, a necessary condition is that factor would have to be X times more common in exposed versus unexposed persons.[@B25]

For each drug with an SDR for the ADE PT (PT ~ADE~) pneumothorax we reviewed the reported drug-indications to identify the most significant confounders for this event based on current clinical knowledge. From the latter indications for each drug, we searched for those that were prominently represented based on the number of reports (and therefore representative indications for that drug) and that were likely to be quantitatively most influential on our calculations based on higher EBGMs. If more than one likely candidate confounding indication was identified all were considered and included in the outputs.

Reporting of indications may be inherently different than reporting of events since the former are not necessary to create an ADE report but the latter are a required minimum data element, and because reporting of indications may be more deterministic and less stochastic than events. That is, the drug is nonrandomly selected for specific indications whereas many ADEs are typically the result of multiple random and nonrandom factors. Therefore the range of ADEs reported with a drug is expected to be much wider than the range of reported indications. We therefore introduced an adjustment based on the reduced range of unique indication PTs (PTs ~IND~) recorded in the database relative to the range of unique PTs ~ADE~, both overall in the database and preferentially for specific drugs. Expressed a little differently the number of unique reported indications in the entire database is less than the number of unique reported ADEs in the entire database and all else being equal, the difference between reported indications and reported ADEs may be larger or smaller for specific drugs depending on the overall safety profile and the number of treatment indications. The idea is to give a "more severe" test, (e.g. part of a best case-worst case scenario) for whether CBI is quantitatively plausible within the set of ADE reports. We calculated the number of unique PTs ~ADE~ and PTs ~IND~ for the overall database and for the specific subset of drugs with statistically significant reporting relationship. The ratio of these two in the overall database may be viewed as an adjustment for expected indication counts, and that for specific drugs as an adjustment for observed indication counts. Expressed a little differently we isolated the component of observed and expected counts for indication related to the distribution of counts within the reduced range of PTs ~IND~ for each drug. The adjusted CBI index (ACBII) was therefore calculated as follows:
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The more the ACBIIs metric exceeds one the more it suggest that the restriction of the reported indications to confounding indications is substantial relative to the magnitude of the SDR. We thus are comparing SDRs for drug-ADE pairs and drug-indications pairs, which we denote by SDR~ADE~and SDR~IND~.

Results
=======

There were 878 unique reported suspect drugs, (either single drugs or combination products) in 3681 reports recording pneumothorax as an ADE (17% of 5043 total drugs in the database). The 3681 reports of the ADE pneumothorax represents 0.08 % of 4637278 total ADE reports in the database. The number of reports per drug ranged from 1 to a maximum of 115. The majority (821/878 or 93%) of drugs associated with pneumothorax had only a single report compared to 848392/1766279 (48%) of all DECs with only one report.

Fifty-one of the 878 (5.8%) drugs in AERS listing pneumothorax were associated with an SDR (Table1).

The statistical reporting dependencies or SDRs (e.g. O/E reporting that exceeds chance expectation), expressed in the EBGM, ranged from 2.76 to a maximum of 152.2. Six non-oncology drugs accounted for the strongest statistical reporting associations. Pulmonary surfactants accounted for three of these (152.2 for colfoceril, 62.0 for poractant alpha, and 60.1 for beractant), followed by nitric oxide (16.4), pentamidine (14.3) and alglucosidase alpha (9.06). The highest values involving pulmonary surfactants illustrate the potential for CBI through various reporting mechanisms in SRS databases, as these compounds have been documented to actually decrease the incidence of pneumothorax in clinical trials.[@B34] Twenty-six oncology drugs were associated with an SDR~ADE~. The EBGMs for these drugs ranged from 2.76 for oxaliplatin to 8.52 for carmustine.

The CBI analysis (Table [2](#T2){ref-type="table"}) is notable for a wide range of UCBIIs with all drug-specific values \>1, and two drugs, carmustine and docetaxel, with an ACBII consistently \<1. Among the six strongest drug-ADE associations described above, there are potentially confounding indications with significant statistical associations (SDR~IND~) with each drug that are large relative to the magnitude of the SDR~ADE~ as reflected in large UCBIIs and/or ACBIIs greater than one for beractant, nitric oxide, pentamidine, and poractant alpha. The most obvious of these, as discussed qualitatively above, is neonatal respiratory distress syndrome for the pulmonary surfactants beractant and proractant alpha (the precise indications were not recorded in colfosceril reports), which, as stated above, have been shown in clinical trials to decrease the risk of pneumothorax in this condition.[@B34] Pentamidine was notable for a very high ACBII (13.79) consistent with clinicopathological correlates of pneumocystis tissue invasion, inflammation, and necrosis.[@B17] Similarly nitric oxide is used to treat pulmonary hypertension in neonates with pneumothorax and in both of the latter clinical scenarios maximal ventilation may be employed which may cause air leaks.

For the oncology drugs, various carcinomas, sarcomas and lymphomas were potentially confounding indications associated with strong statistical associations with the drug. Carmustine and docetaxel have the largest and fifth largest EBGM among oncology drugs and were the two oncology drugs associated with an ACBII \<1 for the single identified confounding indication for each drug. Of note carmustine is the drug with the most established association with pneumothorax based on the occurrence of upper lobe fibrobullous disease.[@B3] Docetaxel is the one drug for which we were able to identify a case report involving multiple positive rechallenges with each multidrug chemotherapy course.[@B6] However bleomycin, another oncology agent with an established reputation for pulmonary toxicity that could provide a mechanistic context for pneumothorax, had the second largest EBGM and was associated with one of the highest ACBII.

Discussion
==========

We found a significant number of ADE reports of pneumothorax in a large health authority SRS database though it was rare as a proportion of all reports. Most drugs with SDRs were oncology drugs of various mechanisms of action but the strongest statistical associations involved a small number of non-oncology drugs, namely pulmonary surfactants and pentamidine, that our analysis supports as CBI. The results are consistent with pulmonary surfactants\' reported reduction in the incidence of pneumothorax in neonatal respiratory distress syndrome, and clinical-pathological correlates indicating that pneumothorax in the setting of pneumocystis pneumonia may reflect peripheral microbial inflammation, invasion and tissue necrosis corresponding to gradients in aerosol particle deposition.[@B14]-[@B17] Of note ACBIIs for the surfactant preparations for which indication was reported were all greater than one and for pentamidine was 13.79. The two oncology drugs with a consistent finding of an ACBII \<1 seem to have the most persuasive association with pneumothorax from independent datasets. Therefore this approach to CBI analysis showed preliminary hints of utility for initial exploratory analysis to provide quantitative support for initial understanding and triage of SDRs in PhV. The absence of obvious confounding indications does not necessarily rule out CBI as a causal or contributory factor. In some instances the absence of an obvious recorded indication was due to the fact that the indication was not reported in any reports (i.e. colfosceril). In other instances the reported indication could have been a confounding factor, though not as well established as in the classic examples of various oncology drugs. For instance the reported indication for alglucosidase alpha was glycogen storage disease type II, which involves serious pulmonary disease that could at least theoretically be associated with pneumothorax via natural history or iatrogenic disease.[@B35]

There are significant limitations to our analysis most notably the usual \'warnings, precautions and indications for use\' for SRS data which precludes making causal inferences except in unusual circumstances[@B24] which are amplified by the aforementioned differences in event versus indication reporting. We did not perform a case-level clinical review (case narratives are not included in AERS extracts for public use) and results of any quantitative analysis of SRS data is most meaningful when correlated with case-level clinical information. DA is based on 2x2 contingency tables methods and therefore do not accommodate the complex multivariate drug and event relationships that are characteristic of such data and which may be especially pertinent to the oncology setting where multi-drug treatment protocols are common. For example, the pulmonary toxicity of docetaxel has been reported to be enhanced by co-administered gemcitabine.[@B36],[@B37] Finally like any observational database, and perhaps especially so for SRS data, there are other reporting artifacts such as unrecorded confounding and effect modification which this approach does not address and which typically remain unresolved in initial signal detection in PhV.

The application of even basic disproportionality analysis has been the subject of heated debate with extreme viewpoints of "unbridled optimism" to "considerable skepticism".[@B38] In other words some authorities consider such analysis a "garbage in garbage out" exercise of no value and potential harm, while others unrealistically maintain that such quantitative analysis, if performed with certain proprietary software, can neutralize the enormous limitations of spontaneous reports. We take a moderate position between the aforementioned extremes. With our analysis, which went beyond the usual drug-ADE analysis to include a drug-indication analysis, so one must be even more cautious in interpretation.

While the above limitations are substantial and clearly disqualifies this approach for making inferences, it is does not necessarily disqualify its judicious application as an exploratory analysis tool to help refine an initial index of suspicion related to CBI. Quoting an author writing about another exploratory analysis tool[@B39] "data mining and fishing expeditions are dirty words, but tempered with an awareness of the fallacies they can lead to, and supported by honest documentation, it is not a scientific crime" to use them in this context to search for a possible contribution of CBI to the reporting association between the drug and the event.

An analysis using Cornfields\'s inequality in this setting has advantages including the fact that it is simply an extension of the same basic calculation used for the drug-ADE pair to drug-indication pairs and thus easily implementable for front-end signal detection in PhV, as well as being transparent and intuitive but there are other alternative approaches including calculating O/E ratios within different levels of a confounding variable and/or calculating an adjusted summary measure as with Mantel-Haenzsel methods (as we did with age, gender and reporting year). Another approach applied to SRS data is to perform the DA on a subset of drugs within a pharmacological/therapeutic class or for specific indication(s).[@B40]-[@B48] Although this has been performed at times there are limitations to these approaches as well. For example depending on the specific implementation of the DA such an approach can potentially mask[@B24] credible associations if they exist with multiple drugs within the pharmacological/therapeutic class. Utilizing the generality of the database as a background may provide a better picture of the statistical reporting associations in the universe of drugs, rather than just differences between drugs within a subset of drugs. This may inevitably entail a trade-off between sensitivity and specificity. Finally such an approach allows analysis of only one drug class per analysis.

Finally our adjustment, while based on plausibility considerations, is still essentially somewhat ad hoc, (as are many exploratory analysis in PhV) but it provides a starting point for further discussion and research including a systematic assessment of its operating characteristics, as well as that of other potential adjustment factors. It would also be interesting to perform a systematic study to establish operating characteristics of U/ACBII that could potentially identify optimum thresholds that might obviate the need for correction.

Manfred Hauben was responsible for the initiation and design of the study as well as manuscript writing and editing. Eric Hung was responsible for the data generation and review and editing of the manuscript. Both authors take responsibility for the manuscript content.

###### 

Drug-PT~ADE~ (Pneumothorax) Pairs Associated with an SDR~ADE~

  Generic Name                     PT~ADE~        N     EB05   EBGM    EB95
  -------------------------------- -------------- ----- ------ ------- -------
  Colfosceril                      Pneumothorax   9     84.1   152.2   258.4
  Poractant Alfa                   Pneumothorax   9     34.3   62.0    105.3
  Beractant                        Pneumothorax   11    35.3   60.1    97.1
  Nitric Oxide                     Pneumothorax   19    9.77   16.4    24.4
  Pentamidine                      Pneumothorax   11    5.58   14.3    27.4
  Alglucosidase Alfa               Pneumothorax   18    5.3    9.06    15.8
  Carmustine                       Pneumothorax   15    4.75   8.52    16.2
  Dacarbazine                      Pneumothorax   13    4.18   7.57    15.3
  Bleomycin                        Pneumothorax   22    4.46   6.52    9.59
  Gefitinib                        Pneumothorax   32    4.75   6.45    8.7
  Docetaxel                        Pneumothorax   86    5.25   6.3     7.51
  Bevacizumab                      Pneumothorax   104   4.76   5.6     6.57
  Vinblastine                      Pneumothorax   13    3.29   5.35    8.58
  Epoprostenol                     Pneumothorax   13    3.06   4.94    7.74
  Actinomycin-D                    Pneumothorax   10    2.83   4.92    8.39
  Carboplatin                      Pneumothorax   80    4.05   4.89    5.85
  Dornase Alfa                     Pneumothorax   6     2.16   4.56    10.9
  Gemcitabine                      Pneumothorax   70    3.69   4.51    5.46
  Leflunomide                      Pneumothorax   31    3.27   4.42    5.88
  Etoposide                        Pneumothorax   52    3.47   4.38    5.47
  Paclitaxel                       Pneumothorax   81    3.57   4.3     5.14
  Ifosfamide                       Pneumothorax   18    2.78   4.14    6
  Vinorelbine                      Pneumothorax   21    2.82   4.08    5.75
  Everolimus                       Pneumothorax   22    2.75   3.94    5.51
  Pamidronic Acid                  Pneumothorax   23    2.76   3.92    5.44
  Erlotinib                        Pneumothorax   24    2.75   3.88    5.35
  Doxorubicin                      Pneumothorax   61    3.04   3.76    4.62
  Mycophenolic Acid Slow Release   Pneumothorax   8     2.04   3.72    6.39
  Vincristine                      Pneumothorax   55    2.85   3.58    4.44
  Ambrisentan                      Pneumothorax   19    2.42   3.57    5.11
  Methylprednisolone               Pneumothorax   40    2.57   3.35    4.31
  Hydrocortisone                   Pneumothorax   13    2.09   3.34    5.12
  Prednisolone                     Pneumothorax   45    2.5    3.2     4.06
  Amiodarone                       Pneumothorax   40    2.46   3.2     4.12
  Methotrexate                     Pneumothorax   75    2.64   3.2     3.85
  Trastuzumab                      Pneumothorax   16    2.09   3.18    4.69
  Melphalan                        Pneumothorax   17    2.11   3.18    4.64
  Dexamethasone                    Pneumothorax   40    2.44   3.18    4.09
  Midazolam                        Pneumothorax   18    2.14   3.18    4.59
  Bosentan                         Pneumothorax   28    2.3    3.16    4.26
  Cisplatin                        Pneumothorax   59    2.5    3.11    3.83
  Pemetrexed                       Pneumothorax   19    2.09   3.08    4.41
  Heparin                          Pneumothorax   47    2.37   3.03    3.82
  Azathioprine                     Pneumothorax   21    2.07   2.99    4.2
  Sunitinib                        Pneumothorax   34    2.24   2.99    3.92
  Botulinum Toxin Type A           Pneumothorax   23    2.06   2.93    4.07
  Tacrolimus                       Pneumothorax   41    2.24   2.91    3.73
  Propofol                         Pneumothorax   21    2      2.89    4.07
  Cyclophosphamide                 Pneumothorax   62    2.29   2.83    3.47
  Palivizumab                      Pneumothorax   27    2.04   2.82    3.82
  Oxaliplatin                      Pneumothorax   30    2.03   2.76    3.68

###### 

Analysis of Spontaneous Reporting Pneumothorax

                               PT~ADE~: Pneumothorax   Confounding Indication\*   PTs ~ADE~/PTs ~IND~   (O/E)~IND~/ (O/E)~ADE~                                                                  
  ---------------------------- ----------------------- -------------------------- --------------------- ---------------------------------- ------- ------- -------- ---------- ------- -------- -------
  Actinomycin-D                10                      2.83                       4.92                  Nephroblastoma                     56      243.3   304.9    829/85     9.75    61.97    11.06
  Rhabdomyosarcoma             148                     124.3                      142.6                 28.98                              5.17                                                 
  Alglucosidase alpha          18.3                    5.03                       9.06                  NA                                 NA      NA      NA       NA         NA      NA       NA
  Ambrisentan                  19                      2.42                       3.57                  NA                                 NA      NA      NA       NA         NA      NA       NA
  Azathioprine                 21                      2.07                       2.99                  NA                                 NA      NA      NA       NA         NA      NA       NA
  Beractant                    11                      35.3                       60.1                  Neonatal resp distress synd        8       297.3   560.3    115/11     10.45   9.32     1.55
  Bevacizumab                  104                     4.76                       5.6                   Colorectal cancer metastatic       1319    64.8    67.8     3083/467   6.60    12.11    3.19
  Non-small cell lung cancer   1193                    17                         17.8                  3.18                               0.84                                                 
  Bleomycin                    22                      4.46                       6.523                 Hodgkin\'s disease                 511     345.1   371.3    1386/180   7.70    56.93    12.86
  Testis cancer                150                     344.3                      394.6                 60.50                              13.67                                                
  Carboplatin                  80                      4.05                       4.89                  Non-small cell lung cancer         2278    43.6    45.2     3143/539   5.83    9.24     2.76
  Lung neoplasm malignant      690                     30.5                       32.4                  6.63                               1.98                                                 
  Carmustine                   15                      4.75                       8.52                  Non-Hodgkin\'s lymphoma            55      29.5    37       1052/119   8.84    4.34     0.85
  Cisplatin                    59                      2.5                        3.11                  Sm cell lung cancer stage unspec   414     52.5    56.9     3320/623   5.33    18.30    5.97
  Oesophageal carcinoma        335                     44.1                       48.3                  15.53                              5.07                                                 
  Non-small cell lung cancer   1484                    23.9                       24.9                  8.01                               2.61                                                 
  Colfosceril                  9                       84.1                       152.2                 NA\*\*                             NA      NA      NA       NA         NA      NA       NA
  Cyclophosphamide             62                      2.29                       2.83                  Breast cancer                      2667    21.9    22.6     4259/915   4.65    7.99     2.99
  Dacarbazine                  13                      4.18                       7.57                  Metastatic malignant melanoma      87      328.1   392.8    804/91     8.84    51.89    10.22
  Malignant melanoma           158                     191.5                      218.7                 28.89                              5.69                                                 
  Docetaxel                    86                      5.25                       6.3                   Non-small cell lung cancer         868     18.6    19.7     3116/436   7.15    3.13     0.76
  Doxorubicin                  61                      3.04                       3.76                  Breast cancer                      1597    15.5    16.2     3574/638   5.60    4.31     1.34
  Erlotinib                    24                      2.75                       3.88                  Lung neoplasm malignant            687     70.4    75       2050/236   8.69    19.33    3.87
  Non-small cell lung cancer   1328                    53.9                       56.4                  14.54                              2.91                                                 
  Etoposide                    52                      3.47                       4.38                  Sm cell lung cancer stage unspec   476     137.1   147.9    2865/540   5.31    33.77    11.07
  Gefitinib                    32                      4.75                       6.45                  Lung adenocarcinoma                453     190.9   206.3    1587/252   6.30    31.98    8.84
  Non-small cell lung cancer   1056                    46.4                       48.8                  7.57                               2.09                                                 
  Gemcitabine                  70                      3.69                       4.51                  Non-small cell lung cancer         1621    30.3    31.5     3159/498   6.34    6.98     1.92
  Ifosfamide                   18                      2.78                       4.14                  Sarcoma                            135     220.8   255      1609/331   4.86    61.59    22.05
  Oxaliplatin                  30                      2.03                       2.76                  Colon cancer                       1426    75.9    79.3     2450/312   7.85    28.73    6.37
  Colorectal cancer            1047                    44.8                       47.1                  17.07                              3.78                                                 
  Melphalan                    17                      2.11                       3.18                  NA                                 NA      NA      NA       NA         NA      NA       NA
  Methotrexate                 75                      2.64                       3.2                   NA                                 NA      NA      NA       NA         NA      NA       NA
  Nitric Oxide                 19                      9.8                        16.4                  Pulmonary Hypertension             49      85.8    109.2    237/62     3.82    6.67     3.04
  Paclitaxel                   81                      3.57                       4.3                   Non-small cell lung cancer         1598    27.8    29       3343/473   7.07    6.74     1.66
  Lung neoplasm malignant      692                     27.6                       29.4                  6.84                               1.68                                                 
  Pemetrexed                   19                      2.09                       3.08                  NA                                 NA      NA      NA       1748/192   9.1     NA       NA
  Pentamidine                  11                      5.6                        14.3                  Pneumocystis jiroveci pneumonia    23      522.9   748.3    587/89     6.60    52.26    13.79
  Poractant Alfa               9                       34.3                       62                    Neonatal resp distress synd        26      779.1   1090.4   132/15     8.80    17.59    3.48
  Sunitinib                    34                      2.24                       2.99                  Metastatic renal cell carcinoma    2170    64.6    66.9     2251/337   6.68    22.37    5.83
  Renal cell carcinoma         2546                    50.5                       52.2                  17.46                              4.55                                                 
  Trastuzumab                  16                      2.09                       3.18                  Breast cancer metastatic           778     56.8    60.3     2107/159   13.25   18.96    2.49
  Breast cancer                2177                    35.9                       37.2                  11.70                              1.54                                                 
  Vinblastine                  13                      3.29                       5.35                  Hodgkin\'s disease                 385     495.6   539.3    1190/133   8.95    100.80   19.60
  Vincristine                  55                      2.85                       3.58                  Non-Hodgkin\'s lymphoma            1009    55.9    58.8     3593/602   5.97    16.42    4.79
  Vinorelbine                  21                      2.82                       4.08                  Non-small cell lung cancer         677     47.2    50.3     1786/172   10.38   12.33    2.07

The overall ratio of PT~ADE~/PT~IND~ in the database= 15005/8646=1.73

\*"NA"-no obvious confounding indications identified in any reports

\*\*Specific indications not reported
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